Cipla To Pour $460 Million Into Production Expansion In India
This article was originally published in PharmAsia News
India's Cipla says it plans to invest nearly $460 million during the next two years as part of its expansion policy to produce more drugs for domestic and foreign consumption. The funds are to be added to a program already building new facilities and expanding others to take advantage of an anticipated 12 percent to 15 percent growth next year. Part of that growth is expected to be generated by a 10 percent growth in company exports, already comprising half of its business. (Click here for more
You may also be interested in...
An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.
Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.